MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis

 MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis

MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis

Shots:

  • The discontinuation of a clinical program is based on an interim analysis for futility in P-II IGUANA study which demonstrated low probability to meet 1EPs i.e, the percentage change in EASI score
  • The clinical development program of MOR106 includes two P-II IGUANA & GECKO studies, P-I bridging study for SC formulation and Japanese ethno-bridging study. All the studies evaluating MOR106 in AD will be terminated
  • MOR106 is a mAb targeting IL-17C, jointly discovered by Galapagos and MorphoSys. In July’2019, Galapagos and MorphoSys signed an exclusive WW development and commercialization agreement with Novartis for MOR106

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Hin.be

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post